Seattle, WA -- (SBWIRE) -- 10/07/2019 -- Bone Degeneration Therapeutics Market Overview

Deterioration of articular cartilage covering the joints is called bone degeneration. The joints rely on cartilages for free movement without any resistance. Deterioration of cartilage can lead to decrease in flexibility of the joint and can cause inflammation, compressed nerves, and pain. One of the natural and common causes on bone degeneration is aging and increases due to several conditions such as injuries, congenital disorders, diabetes, and obesity. Some of the symptoms of degenerative bone disorders include joint stiffness, radiating pain that initiates in the back and spreads through the extremities and causes joint inflammation.

Download PDF Brochure with Detailed Analysis @ https://www.coherentmarketinsights.com/insight/request-pdf/94

Osteoporosis

The two levels of bone loss that can increase the risk of fractures include osteoporosis and osteopenia. Osteopenia is characterized by loss of bone material density that decreases the thickness of the bones. Osteoporosis is characterized by the existence of porous bones. The gradually increasing condition is evident as bones slowly lose minerals, structure, and density, resulting in weaker bones. Osteoporosis leads to bent posture, cracked bones, and loss of height. 

Excessive bone degeneration can be a major cause of fragile bones, which are at risk of fracture. Bone densitometers and dual energy x-ray absorptiometry scans can be performed to determine the density of Some of the methods of reducing pain resulting from degenerative bone disorders include stimulation of soft tissues and cartilage repair with prolotherapy.

Increasing prevalence of diabetes and obesity is expected to boost growth of the bone degeneration therapeutics market

Increasing physical inactivity and high prevalence of obesity and diabetes is expected to boost growth of the bone degeneration therapeutics market. According to World Health Organization, (WHO) around 422 million people worldwide suffered from diabetes in 2014. 

Increasing number of products in pipeline is expected to boost growth of the bone degeneration therapeutics market

The bone degeneration therapeutics market is segmented by treatment and application. On the basis of treatment, the market is further segmented into device, drug, and surgery. Braces or sleeves are used to relieve pain caused due to bone degeneration and offer pain relief to orthopedic patients. On the basis of drugs, the bone degeneration therapeutics market is segmented into cortisone or steroids, hyaluronic acid and platelet-rich plasma. Platelet-rich plasma can reduce pain due to arthritis of the knee. Major companies such as Bone Therapeutics SA is developing products such as PREOB and ALLOB. In March 2008, the U.S. FDA granted orphan drug designation to PREOB for osteonecrosis. On the basis of surgery, the bone degeneration therapeutics market is segmented into arthroscopy, high tibial osteotomy, and knee replacement. On the basis of application, the bone degeneration therapeutics market is segmented as osteoporosis, osteopenia, and spinal fusion.

Denosumab injection (Prolia) is used for the treatment of osteoporosis in men, post-menopausal women, people with increased risk for fractures, and those who cannot take or do not respond to other medications for osteoporosis. It is also used for the treatment of bone loss in men suffering from prostate cancer and women with breast cancer.

Increasing incidences of sports injuries and increasing geriatric population is expected to boost growth of the bone degeneration therapeutics market in North America

The market in North America is expected to witness significant growth, owing to high incidence of sport injuries, increasing geriatric population, robust medical infrastructure, and favorable government reimbursement policies. For instance, according to 2016 estimates of Osteoporosis Canada, over 80% of all  fractures reported in people over 50 years of age are caused by osteoporosis and at least one in three women and one in five men suffer from an osteoporotic fracture during their lifetime.

The market in Asia Pacific is expected to witness significant growth, owing to increasing health awareness and development of good diagnostic and treatment facilities in the region.

Bone degeneration therapeutics market: Key players

Key players operating in the bone degeneration therapeutics market include, Amgen, Inc., Fate Therapeutics, Inc., Bone Therapeutics SA, Juventus Therapeutics, Inc., Kaken Pharmaceutical Co., Ltd., Regenexx, and Se-cure Pharmaceuticals Ltd. Regenexx stem cell and platelet-rich plasma procedures are advanced regenerative therapies used for the treatment of knee pain due to arthritis, ligament injuries, and other degenerative conditions.

For More Details About Bone Degeneration Therapeutics Market At: https://www.coherentmarketinsights.com/ongoing-insight/bone-degeneration-therapeutics-market-94

Bone degeneration therapeutics market: Key Developments

Key players in the market are focused on conducting human surgical procedures with novel therapies to expand their product portfolio. For instance, in August 2019, Anika Therapeutics, Inc., an integrated orthopedic and regenerative medicines company, announced the successful completion of first human surgical procedure with injectable HA-based bone repair therapy for the treatment of bone voids and other bone defects of the skeletal system caused by trauma or age-related degeneration.

Major institutes are focused on research and development activities related to bone degeneration. For instance, in July 2019, a team of researchers from the University of California reported in a research published in the journal Arthritis Care and Research that Vitamin D supplementation reduces cartilage degeneration and progression of knee osteoarthritis. Such researches are expected to promote longitudinal randomized controlled trials of vitamin D supplementation, which may offer lucrative growth opportunities for the market players.

Key players in the market are focused on gaining product approvals to expand their product portfolio. For instance, in August 2019, the U.S. FDA cleared the NEXXT MATRIXX Stand Alone Cervical System of Nexxt Spine LLC for commercial sale via the 510(k) process. The system is intended for use as an adjunct to fusion at one or two contiguous levels (C2-T1) in skeletally mature patients for the treatment of degenerative disc disease.

Buy Now This Report @ https://www.coherentmarketinsights.com/insight/buy-now/94

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.